ArticleEBioMedicine2016
The Impact of Alzheimer's Disease on the Chinese Economy.
Article in EBioMedicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The economic burden of dementia in low- and middle-income countries (LMICs): a systematic review.BMJ global health · 2022Pooled it
- Association of CD14-260 (-159) C/T and Alzheimer's disease: systematic review and trial sequential analyses.Journal of neural transmission (Vienna, Austria : 1996) · 2018Pooled it
- Cerebral Venous Insufficiency as a Contributing Factor in Dementia: An Emerging Hypothesis.Stroke (Hoboken, N.J.) · 2026Review
- The Expanding Burden of Neurodegenerative Diseases: An Unmet Medical and Social Need.Aging and disease · 2024Review
- Cationic Surface Charge Engineering of Recombinant Transthyretin Remarkably Increases the Inhibitory Potency Against Amyloid β-Protein Fibrillogenesis.Molecules (Basel, Switzerland) · 2024Article
- Difference of Cerebrospinal Fluid Biomarkers and Neuropsychiatric Symptoms Profiles among Normal Cognition, Mild Cognitive Impairment, and Dementia Patient.International journal of molecular sciences · 2024Article
- Potential Regulatory Role of miR-21 on Alzheimer's Disease by Targeting GSK-3β Signaling.Galen medical journal · 2023Article
- Inhibiting Autophagy Pathway of PI3K/AKT/mTOR Promotes Apoptosis in SK-N-SH Cell Model of Alzheimer's Disease.Journal of healthcare engineering · 2022Article
- Factors Associated With Alzheimer's Disease Patients' Caregiving Status and Family Caregiving Burden in China.Frontiers in aging neuroscience · 2022Article
- Secular Trends in the Incidence of and Mortality Due to Alzheimer's Disease and Other Forms of Dementia in China From 1990 to 2019: An Age-Period-Cohort Study and Joinpoint Analysis.Frontiers in aging neuroscience · 2021Article
- Estimating the global economic benefits of physically active populations over 30 years (2020-2050).British journal of sports medicine · 2020Article
- Anticipated Social and Healthcare Economic Burden of People with Alzheimer's Disease in Two Selected Regions of the Czech Republic.Healthcare (Basel, Switzerland) · 2020Article
- Association between plasma exosome neurogranin and brain structure in patients with Alzheimer's disease: a protocol study.BMJ open · 2020Article
- Study design and baseline characteristics of Shenzhen ageing-related disorder cohort in China.BMJ open · 2020Article
- Barriers to dementia diagnosis and care in China.BMJ case reports · 2020Article
- Farnesoid X Receptor (FXR) Aggravates Amyloid-β-Triggered Apoptosis by Modulating the cAMP-Response Element-Binding Protein (CREB)/Brain-Derived Neurotrophic Factor (BDNF) Pathway In Vitro.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- A Weighted Genetic Risk Score Based on Four APOE-Independent Alzheimer's Disease Risk Loci May Supplement APOE E4 for Better Disease Prediction.Journal of molecular neuroscience : MN · 2019Article
- Deep learning-based classification of multi-categorical Alzheimer's disease data.Current neurobiology · 2019Article
- Evidence on the magnitude of the economic, health and population effects of palm cooking oil consumption: an integrated modelling approach with Thailand as a case study.Population health metrics · 2019Article
- An individualised, non-pharmacological treatment strategy associated with an improvement in neuropsychiatric symptoms in a man with dementia living at home.BMJ case reports · 2019Article
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
Abstract
backgroundRecent increases in life expectancy may greatly expand future Alzheimer's Disease (AD) burdens. China's demographic profile, aging workforce and predicted increasing burden of AD-related care make its economy vulnerable to AD impacts. Previous economic estimates of AD predominantly focus on health system burdens and omit wider whole-economy effects, potentially underestimating the full economic benefit of effective treatment.
methodsAD-related prevalence, morbidity and mortality for 2011-2050 were simulated and were, together with associated caregiver time and costs, imposed on a dynamic Computable General Equilibrium model of the Chinese economy. Both economic and non-economic outcomes were analyzed.
findingsSimulated Chinese AD prevalence quadrupled during 2011-50 from 6-28 million. The cumulative discounted value of eliminating AD equates to China's 2012 GDP (US$8 trillion), and the annual predicted real value approaches US AD cost-of-illness (COI) estimates, exceeding US$1 trillion by 2050 (2011-prices). Lost labor contributes 62% of macroeconomic impacts. Only 10% derives from informal care, challenging previous COI-estimates of 56%.
interpretationHealth and macroeconomic models predict an unfolding 2011-2050 Chinese AD epidemic with serious macroeconomic consequences. Significant investment in research and development (medical and non-medical) is warranted and international researchers and national authorities should therefore target development of effective AD treatment and prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.